XML 36 R27.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Other current assets $ 503   $ 537
Current prepaid expense 200    
current unbilled receivables 200    
Other current receivables $ 100    
Share-based compensation arrangement by share-based payment award, expiration period 10 years    
Stock-based compensation expense $ 110 $ 114  
Unrecognized compensation expense related to unvested stock awards, not yet recognized $ 300    
Unvested stock options, unrecognized compensation expense weighted average recognition period 1 year 4 months 1 day    
Stock options, granted (in shares) 14,000 12,350  
Stock options, fair value assumptions, risk free interest rate (as a percent) 1.91%    
Stock options, fair value assumptions, dividend yield 0.00%    
Stock options, fair value assumptions, expected life 6 years    
Stock options, fair value assumptions, historical volatility rate (as a percent) 85.00%    
Common stock rights issued (in shares) 2,933,106 1,208,491  
Deferred revenue $ 192   217
Options, warrants and conversion rights, common stock callable and antidilutive (in shares) 12,970,881 8,248,953  
Pharmacogenomic Services      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Deferred revenue $ 200   $ 200
Executive Officers      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock options, unvested options, vesting period 3 years    
Common stock rights issued (in shares) 98,333    
Selling, General and Administrative Expenses      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense $ 100 $ 100  
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock options, unvested options, vesting period 3 years    
Familion | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Estimated Useful Life   7 years  
Familion | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Estimated Useful Life   15 years